Das Zentrum
Multiple Sklerose Zentrum Dresden
Patienteninformation
Kontaktinformation
Behandlungsteam
Studienteam
Neuropsychologie
Mobilitätszentrum
Das Mobilitätszentrum
Ganganalyse
Sprunganalyse
DIERS
EMIQ
Forschungsprojekte
Neuroimmunologisches Labor
Das NIL
Neurofilament-Leichtketten Analyse
Autonomes & Neuroendokrinologisches Funktionslabor
Das ANF
Untersuchungsmethoden
MS Living Lab
Management & Science
Team Management & Science
Projekte
eHealth & Analytics
MSDS 3D
MSDS Klinik & Praxis
MS-HRS
MTRS
MS Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
Deutsch
Deutsch
English (UK)
Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE
Mobility
Jahr
Publikationsjahr
2022
Autoren
Autorenliste der Publikation
Hupperts R, Gasperini C, Lycke J, Ziemssen T, Feys P, Xiao S, Acosta C, Koster T, Hobart J.
Verlag
Publisher-Information
Ther Adv Neurol Disord. 2022 May 18;15:17562864221090398.
Link
Zur Publikation (externer Server)
https://doi.org/10.1177/17562864221090398
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Mobilität
Treatments
MSZ
2022
MOBI
Optical coherence tomography as a potential surrogate marker of dopaminergic modulation across the life span
ANF
Jahr
2024
Toward mechanistic medical digital twins: some use cases in immunology
MASC
Jahr
2024
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis
Multiple Sclerosis
Jahr
2024
Insights from Real-World Practice: The Dynamics of SARS-CoV-2 Infections and Vaccinations in a Large German Multiple Sclerosis Cohort
NIL
Jahr
2024
Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis
MASC
Jahr
2024